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involved elective mediastinal lymph node irradiation (ELNI). With the 
advent of dose escalation and new technologies (ie. PET, 4D-CT, IMRT 
etc.), there has been a shift in treatment philosophy in the last few 
years to only including involved mediastinal nodes, which has been the 
policy at Princess Margaret Hospital, a tertiary care academic facility, 
since June 2004. We have been participating in a prospective random-
ized phase III study in Stage III NSCLC, which requires ELNI. Due 
to the difference between the institutional and study policies and the 
availability of new technologies, we reviewed the radiation treatment 
volumes of patients entered onto this study. The objective of this study 
is to determine the compliance of ELNI in this patient population.
Methods: Since September 2004 we have entered 43 patients (pts) onto 
this phase III study, which randomizes pts to PET vs no PET imaging. 
The protocol deﬁnes target volumes to include the primary tumor, ipsi-
lateral hilar lymph nodes and atleast the ipsilateral mediastinal lymph 
nodes up to the level of the clavicle and the subcarinal lymph nodes to 
atleast 3 cm below the carina regardless of the site of the primary tu-
mor. Our departmental policy deﬁnes target volumes that only include 
known mediastinal disease. We analyzed all 43 cases by reviewing 
the DRR’s (digitally reconstructed radiographs) and the plans in the 
Pinnacle radiotherapy planning system for compliance to the protocol 
target volumes.
Results: Twenty-two pts were randomized to the PET arm of the study 
and of these, 15 pts received radical radiation treatment (with concur-
rent chemotherapy). Two of the 15 received pre-operative doses of 
45Gy as part of trimodality treatment (chemotherapy, radiation and 
surgical resection), while the remaining 13 received radical doses with 
a median of 65Gy (3 pts IMRT, 10 pts 3-D conformal). Of the 21 pts 
randomized to the non-PET arm, 18 received radical radiation treat-
ment (3 pts - pre-op 45Gy, 15 pts - median 65Gy, 4 pts IMRT, 11 pts 
3-D conformal). Only one patient in each arm did not have their EMLN 
covered as per protocol. Both pts had IIIA disease involving the left 
lower lobe but did not have the upper mediastinal lymph nodes covered 
in the target volume. 
Conclusions: In this study, despite the difference in policy to include 
only known mediastinal lymph nodes and the availability of new tech-
nologies that tend to help support this shift in policy, we were able to 
for the most part adhere to protocol guidelines, which includes ELNI. 
The reasons for compliance to the protocol are multifactorial: a signiﬁ-
cant proportion of the pts in this study population had such extensive 
disease that resulted in large target volumes which inadvertently met 
the protocol guidelines; weekly review rounds to help ensure protocol 
compliance; and meticulous planning on the part of the treating Radia-
tion Oncologist.
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Background: The Gross Tumor Volume (GTV) is an important prog-
nostic factor in NSCLC radiotherapy. CT is the imaging standard for 
target delineation however functional imaging with (FDG) PET is now 
widely available. Integrating PET into CT-guided GTV delineation of-
ten changes the target volume and may reduce inter-observer variation 
however the appropriateness of these changes has not been established. 
And while PET currently shows promise in identifying the presence 
and general location of disease it is unproven as a tool for accurate, pre-
cise radiation targeting. At the present time the spatial resolution and 
image quality of PET are limited, the tumor edge location is unknown 
and it is currently unclear how best to view PET images so that they 
reﬂect actual geometry. Further work is needed to validate co-registered 
PET-CT as a tool for radiation targeting in NSCLC in order to maxi-
mise the probability of eradicating tumor. 
Hypothesis: Radiology-pathology correlation studies will help to 
clarify the relationship between pathological tumor (gold-standard), 
PET and CT dimensions in NSCLC. This will increase understanding 
of how to delineate the GTV using combined PET-CT and improve the 
accuracy of radiation targeting and the therapeutic ratio. This abstract 
reports pilot data on the difference between pathology, PET and CT 
dimensions from 6 patients enrolled in an ongoing study. 
Methods: The 3 greatest naked eye gross pathology, pre-operative PET 
(L22000/W2000, cursor placed at 50% of maximum visual intensity) 
and pre-operative CT (Level/Window 1500/-600) dimensions were 
recorded for each of 6 resected NSCLC tumors.
Results: Normalizing the pathology measurements to 100%, the range 
and median difference between these and the PET-CT measurements 
were as follows (n=18): PET range 78-214% of pathology, median 
115%; CT range 69-171%, median 108%. The Pearson correlation co-
efﬁcient between PET and pathology was 0.96, CT and pathology 0.97, 
and CT and PET 0.98 (n=18, p<0.05 for all).
Conclusion: Acknowledging the small sample size, this hypothesis-
generating pilot data suggests that when using the image settings and 
segmentation described, statistically signiﬁcant correlation exists 
between gross pathology, PET and CT tumor size in NSCLC. How-
ever this can obscure large absolute differences that may be clinically 
relevant when delineating individual GTV targets. In this dataset both 
PET and CT tended to overestimate macroscopic pathological tumor 
size as measured on fresh, non-inﬂated tissue. PET size was on average 
larger than CT perhaps reﬂecting the greater inﬂuence of tumor motion. 
Further studies are needed to conﬁrm and characterize these ﬁndings. 
Ideally these require correlation techniques with the ability to identify 
microscopic tumor extension (not detected here), a range of PET-CT 
image settings and segmentation protocols, 4-D CT imaging and mul-
tiple observers. This data provides an impetus for ongoing collaborative 
efforts to develop novel whole mount digital histopathology and 3-D 
image reconstruction methods with which to co-register and compare 
imaging, pathology and radiation treatment volumes. Any uncertainty 
in the use of PET and CT for NSCLC GTV targeting is likely to be-
come increasingly important as treatment margins are reduced and the 
use of intensity modulation and image guidance increases.
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Purpose: To report on the beneﬁt of daily administration of subcutane-
ous amifostine to limit toxicity during dose-escalated radiotherapy (RT) 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS766
to 70 Gy concurrent with chemotherapy in a prospective cohort of poor 
risk unresectable stage III lung cancer patients.
Method: From 8/04 to 10/06, 44 unresectable stage III lung cancer 
patients seen at the Cleveland Clinic were treated with radiotherapy 
consisting of <50Gy to the primary tumor and regional lymph nodes 
followed by a boost to gross tumor for a total dose of 70 Gy. Carboplat-
in (AUC of 2) and paclitaxel (50 mg/m2) were administered concurrent-
ly with RT. At the physicians’ discretion, consolidation docetaxel (75 
mg/m2) was administered every 3 weeks for no more than 3 courses. 
Patients received 500 mg amifostine daily, divided into 2 subcutaneous 
injections, 30 to 60 minutes prior to RT. All received oral antiemetic 
and antihistamine prophylaxis prior to amifostine.
Results: Concerning patient characteristics, median age was 64.5, 
median KPS was 80, 54.5% of patients were female, 77.3% were white, 
93% were former smokers with 14% still smoking. At diagnosis, 24 pa-
tients (54.6%) were stage IIIB, with median tumor size of 3.5 cm. 64% 
of patients received >90% of planned amifostine. Median follow-up 
was 9.8 months. During, at < 90 days and at > 90 days from treatment, 
there was 2.3%, 2.3% and 4.5% grade 3 esophagitis, and 0%, 2.3% 
and 0% grade 3 pneumonitis, respectively, but no grade 4 or 5 toxicity. 
Median survival was 20.8 months and 2-year actuarial survival was 
39%. Median time-to-progression was 13.9 months, with 54.5% having 
no progression at the primary site.
Conclusions: Daily subcutaneous amifostine reduces the rates of 
esophagitis and pneumonitis expected with dose-escalated radiotherapy 
with concurrent chemotherapy, a regimen that may improve survival.
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Objective: Radiation dose is an independent prognostic factor for sur-
vival in patients with early stage non-small cell lung cancer (NSCLC). 
We hypothesized that radiation dose is also a signiﬁcant independent 
factor associated with survival in patients with stage III disease treated 
with combined radiation and chemotherapy. 
Methods: This is an Institutional Review Board approved retrospective 
study. Eligible subjects included those with stage III NSCLC registered 
in the radiation oncology database at University of Michigan Hospital 
between January 1992 and July 2004. Radiation was given using 3-
dimensional conformal technique with doses ranging from 30 to 102.9 
Gy, corresponding to a bioequivalent dose (BED) of 39 to 124.5Gy. 
Median age was 65 years (range, 36-89). There were 80 males and 67 
females. Median follow-up was 13.0 months (range, 2.7-145.9). 
Results: For patients treated with radiation alone (n=40), sequential 
chemoradiation (n=42), and concurrent chemoradiation (n=65), median 
survival was 8.6 (95% CI: 5.7-11.5), 12.8 (95% CI: 9.5-16.0) and 15.4 
(95% CI: 12.7-18.0) months, respectively (P =0 .011). Multivariate 
Cox-regression analysis showed that BED (HR=0.96, 95% CI: 0.95-
0.97, P<0.001) and administration of chemotherapy (HR=0.44, 95% 
CI: 0.28-0.70, P=0.001) were independent prognostic factors associated 
with the risk of death. T stage was marginally signiﬁcant (P=0.065). 
Age, gender, performance, weight loss and N stage were not indepen-
dent factors (P>0.05). To further study the BED effect, multivariate 
analysis was performed separately in patients treated with and without 
chemotherapy: the hazard ratios of BED for the risk of death were 0.97 
(95% CI: 0.95-0.99, P=0 .013) and 0.95 (95% CI: 0.93-0.98, P=0.001), 
respectively. BED also remained a signiﬁcant independent prognostic 
factor in patients treated with chemotherapy and radiation in the dose 
range of 60-66 Gy (HR=0.91, 95% CI: 0.84-0.99, P=0.041).
Conclusions: Radiation dose is signiﬁcantly associated with survival 
in patients with stage III NSCLC treated with combined radiation and 
chemotherapy. 
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Background: A Patterns of Care Study (PCS) was conducted to 
determine the patterns of evaluation and treatment for non-metastatic 
non-small cell lung cancer (NSCLC) in Korea.
Methods: A web-based data system for Korean Patterns of Care Study 
was developed and a national survey was conducted. Patients who 
received thoracic radiotherapy (RT) for clinical or pathologic stage I-III 
NSCLC without other malignancy in 1998 and 1999 were eligible and 
randomly selected by power allocation method.
Results: The records of 446 selected patients from 19 institutions were 
reviewed and 10 patients were excluded because of incomplete clinical 
information. Accordingly, 436 patients were the subject of this study 
with median age of 62.2 years (range, 33.1 - 88.0) and male-to-female 
ratio of 86:14. The histologies were squamous cell carcinoma in 61.2%, 
adenocarcinoma in 28.4%, large cell carcinoma in 2.3%, and NSCLC 
NOS in 8.0% of patients, respectively. Bone scan, abdominal USG or 
CT, brain CT or MRI, and PET was examined in 92.5%, 81.5%, 44.8%, 
and 26.6% of patients, respectively. The clinical stage was I in 8.9%, 
II in 12.2%, IIIA in 37.4%, and IIIB in 41.5%, respectively. Regarding 
treatment modalities, RT was used alone in 38.1%; RT combined with 
operation (OP) in 22.9%; RT combined with chemotherapy (CT) in 
27.1%; trimodalities including RT, OP, and CT in 11.9%. The median 
total dose was 59.4 Gy with daily median fraction size of 1.8 Gy and 
the percent delivered dose over 90% was achieved in 87.6%. Most of 
patients received RT in supine position (99.3%) with beam direction of 
AP/PA (95.6%) as their ﬁrst RT plan, and with photon energy of 6 MV 
(42.0%) followed by 10 MV (41.7%). The CT-based planning was used 
in 2.3 % and 32.6% for their ﬁrst and second RT plan, respectively. The 
three or more RT planning was performed in 13.5% of patients. Elec-
tive nodal irradiation was employed in 87.8% of patients and the N2 
nodal station (48.6%) was most frequently included. The 8% of patients 
received thoracic RT based on prospective protocol. 
Conclusions: This study is the ﬁrst PCF for NSCLC conducted in 
Korea. We conﬁrmed that various types of RT planning were utilized 
according to each institution, but beam delivery techniques were not 
much different in 1998 to 1999. Now another PCS is planned to evalu-
ate changing trends in national practice.
